CD206 ^Replete Mono/Mac signature associates with antitumor immunity in human cancers. (A) Kaplan–Meier survival curves of patients in TCGA grouped by the expression of MRC1 gene. (B and C) (B) UMAP representation of the Mono/Mac subsets and (C) overlay of the CD206 Replete (Ctrl) and depleted (DTx) groups on the UMAP from spatial scSeq described in Fig. 3. (D) Top 10 genes from DGE of Mono/Macs in the Ctrl versus DTx treated conditions, which were used to generate CD206 Replete and CD206 Depleted Mono/Mac signature scores. (E) Expression of select genes defining the CD206 replete (C1qa, Cxcl9, H2-Ab1) and the CD206 depleted (Il1b, S100a8, Spp1) signatures overlaid on the same UMAP. (F) Heatmap of z-scored CD206^Replete, CD8, NK, and SDC score, calculated from sorted immune and live compartments, as previously described (Combes et al., 2022) in colorectal (CRC), gynecological (GYN), head and neck (HNS), kidney (KID), and lung (LUN) cancer patients. (G and H) Scatter plots of the myeloid-specific CD206 Replete and Depleted score per patient with the (G) SDC score and (H) CD8 T cell score (Pearson R and P value for the null hypothesis that there is not a correlation are noted). (I and J) Kaplan-Meier survival curves of patients grouped by the value of the (I) CD206^Replete:CD206^Depleted signature ratio and (J) CD206^Replete signature in TCGA. (K) Expression score for TAMs associated with ICB responsiveness derived from Li et al. (2024) in the CD206^Replete versus CD206^Depleted Mono/Macs; n = 205 patients in G and H; and n = 861 patients per group in I and J; P values for the log-rank test are noted in A, I, and J, and that for the Wilcoxon test is shown in K.